Published online Nov 27, 2018. doi: 10.4254/wjh.v10.i11.849
Peer-review started: June 2, 2018
First decision: July 9, 2018
Revised: July 23, 2018
Accepted: August 21, 2018
Article in press: August 21, 2018
Published online: November 27, 2018
Processing time: 178 Days and 13 Hours
Rates of hepatocellular carcinoma (HCC) continue to increase. Despite new treatment options, mortality rates are also increasing specifically in minority patients.
Given recent emphasis to minimize health care disparities, we aimed to determine if racial disparities in the treatment of HCC were decreasing.
We performed a retrospective database analysis utilizing The Nationwide Inpatient Sample including patients with a diagnosis of HCC. Univariate and multivariate analyses were utilized to determine racial disparities in liver decompensation, treatment, inpatient mortality, and metastatic disease.
This large database analysis included 62604 patients with HCC, including 32428 Caucasian, 9726 African-American, 8988 Hispanic, and 11462 patients of other races. Despite having decreased rates of liver decompensation, African-American patient have higher rates of inpatient mortality and are less likely to undergo curative treatments, such as liver transplantation, surgical resection, or ablation than Caucasian patients.
Racial disparities in HCC treatment exist despite emphasis to support equality in healthcare. African-American patients are less likely to undergo curative treatments for HCC.
Further emphasis should be placed on determining why disparities continue to exist and hypothesize ways to reduce them in order to facilitate equality in healthcare.